Science
Stanford researchers test molecular kill switch to eliminate lymphoma tumors in mice
ScienceDaily reports that the experimental compound TCIP3 turns a cancer-driving protein against tumor cells, clearing them in animal models.
The short version
- Researchers developed TCIP3, a molecule that connects the lymphoma-promoting protein BCL6 with acetyltransferases to trigger programmed cancer cell death.[ScienceDaily]
- Twice-daily administration of TCIP3 eliminated aggressive human lymphoma tumors in mice within 11 days with no observed toxicity.[ScienceDaily]
- The compound also eliminated immune cell clusters known as germinal centers, suggesting potential uses in autoimmune conditions like rheumatoid arthritis.[ScienceDaily]
- The experimental molecule requires additional chemical optimization and testing in other animal species before clinical trials in humans can proceed.[ScienceDaily]
Key facts
- TCIP3 binds BCL6 on one side and acetyltransferases P300 or CBP on the other, promoting acetylation that stops BCL6 from repressing cell death.[ScienceDaily]
- In mouse models, twice-daily treatment with TCIP3 eradicated aggressive human lymphoma tumors in 11 days without evident toxicity or inflammatory increases.[ScienceDaily]
- TCIP3 eliminated germinal centers in mice, leading researchers to explore possible applications in autoimmune diseases.[ScienceDaily]
What remains uncertain
- The experimental compound must undergo further chemical optimization and testing across additional animal species before human trials are feasible.[ScienceDaily]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- Stanford scientists turn a cancer driver into a kill switchScienceDaily - Science